S M Stahl1, P F Buckley. 1. Department of Psychiatry, University of California, San Diego, CA, USA. smstahl@neiglobal.com
Abstract
OBJECTIVE: Negative symptoms of schizophrenia are a common, enduring, and debilitating component of the psychopathology of schizophrenia. Although efforts thus far to elucidate a distinct schizophrenia subtype based upon negative symptoms have yielded mixed results, there are nevertheless neurobiological correlates of the negative symptom typology. METHOD: A review of nosology, typology, and assessment tools for determining core negative symptoms in schizophrenia. RESULTS: Negative symptoms can be difficult to evaluate objectively. Current rating scales 'capture' key domains of negative symptoms, in spite of considerable overlap between these domains. However, each objective assessment trades off methodological rigor and detail against brevity of assessment and ease of use. CONCLUSION: The description of new methods for measuring these devastating symptoms, coupled with the ongoing development of novel antipsychotics and agents that augment antipsychotics have fuelled renewed interest in the evaluation of negative symptoms and optimism that better treatments for negative symptoms can be found.
OBJECTIVE: Negative symptoms of schizophrenia are a common, enduring, and debilitating component of the psychopathology of schizophrenia. Although efforts thus far to elucidate a distinct schizophrenia subtype based upon negative symptoms have yielded mixed results, there are nevertheless neurobiological correlates of the negative symptom typology. METHOD: A review of nosology, typology, and assessment tools for determining core negative symptoms in schizophrenia. RESULTS: Negative symptoms can be difficult to evaluate objectively. Current rating scales 'capture' key domains of negative symptoms, in spite of considerable overlap between these domains. However, each objective assessment trades off methodological rigor and detail against brevity of assessment and ease of use. CONCLUSION: The description of new methods for measuring these devastating symptoms, coupled with the ongoing development of novel antipsychotics and agents that augment antipsychotics have fuelled renewed interest in the evaluation of negative symptoms and optimism that better treatments for negative symptoms can be found.
Authors: Dinesh K Shukla; Joshua John Chiappelli; Hemalatha Sampath; Peter Kochunov; Stephanie M Hare; Krista Wisner; Laura M Rowland; L Elliot Hong Journal: Schizophr Bull Date: 2019-09-11 Impact factor: 9.306
Authors: Ryan D Ward; Vanessa Winiger; Kerin K Higa; Julia B Kahn; Eric R Kandel; Peter D Balsam; Eleanor H Simpson Journal: Behav Neurosci Date: 2015-04-27 Impact factor: 1.912
Authors: Sarah E Bergen; Ayman H Fanous; Po-Hsiu Kuo; Brandon K Wormley; F Anthony O'Neill; Dermot Walsh; Brien P Riley; Kenneth S Kendler Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-03-05 Impact factor: 3.568